189 related articles for article (PubMed ID: 19907933)
1. Lipodystrophy and metabolic complications of highly active antiretroviral therapy.
Parakh A; Dubey AP; Kumar A; Maheshwari A
Indian J Pediatr; 2009 Oct; 76(10):1017-21. PubMed ID: 19907933
[TBL] [Abstract][Full Text] [Related]
2. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.
Piloya T; Bakeera-Kitaka S; Kekitiinwa A; Kamya MR
J Int AIDS Soc; 2012 Jul; 15(2):17427. PubMed ID: 22814353
[TBL] [Abstract][Full Text] [Related]
3. Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.
Bhutia E; Hemal A; Yadav TP; Ramesh KL
Afr Health Sci; 2014 Jun; 14(2):408-13. PubMed ID: 25320591
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.
Sánchez Torres AM; Munoz Muniz R; Madero R; Borque C; García-Miguel MJ; De José Gómez MI
Eur J Pediatr; 2005 May; 164(5):271-6. PubMed ID: 15650834
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy.
Kinabo GD; Sprengers M; Msuya LJ; Shayo AM; van Asten H; Dolmans WM; van der Ven AJ; Warris A
Pediatr Infect Dis J; 2013 Jan; 32(1):39-44. PubMed ID: 23038217
[TBL] [Abstract][Full Text] [Related]
7. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.
Mandal A; Mukherjee A; Lakshmy R; Kabra SK; Lodha R
Indian J Pediatr; 2016 Mar; 83(3):226-31. PubMed ID: 26334860
[TBL] [Abstract][Full Text] [Related]
8. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
[TBL] [Abstract][Full Text] [Related]
9. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART).
Lapphra K; Vanprapar N; Phongsamart W; Chearskul P; Chokephaibulkit K
J Med Assoc Thai; 2005 Jul; 88(7):956-66. PubMed ID: 16241026
[TBL] [Abstract][Full Text] [Related]
10. Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients.
Tomazic J; Silic A; Karner P; Vidmar L; Maticic M; Poljak M; Ihan A; Janez A
Wien Klin Wochenschr; 2004 Nov; 116(21-22):755-9. PubMed ID: 15628647
[TBL] [Abstract][Full Text] [Related]
11. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India.
Pujari SN; Dravid A; Naik E; Bhagat S; Tash K; Nadler JP; Sinnott JT
J Acquir Immune Defic Syndr; 2005 Jun; 39(2):199-202. PubMed ID: 15905737
[TBL] [Abstract][Full Text] [Related]
12. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
[TBL] [Abstract][Full Text] [Related]
13. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
Hirsch HH; Battegay M
Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of first-line, WHO recommended generic HAART regimens in Indian children.
Parakh A; Dubey AP; Kumar A; Maheshwari A; Saxena R
Kathmandu Univ Med J (KUMJ); 2009; 7(27):220-5. PubMed ID: 20071866
[TBL] [Abstract][Full Text] [Related]
15. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe.
European Paediatric Lipodystrophy Group
AIDS; 2004 Jul; 18(10):1443-51. PubMed ID: 15199321
[TBL] [Abstract][Full Text] [Related]
17. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.
Miller J; Carr A; Emery S; Law M; Mallal S; Baker D; Smith D; Kaldor J; Cooper DA
HIV Med; 2003 Jul; 4(3):293-301. PubMed ID: 12859330
[TBL] [Abstract][Full Text] [Related]
18. [Lipodystrophy and echographic hepatic steatosis in HIV-positive patients under highly active antiretroviral therapy (HAART) in Yaounde (Cameroon)].
Ongolo-Zogo P; Nkodo Mbia N; Mvogo Minkala TL; Biwole Sida M; Kouanfack C; Nko Amvene S
Bull Soc Pathol Exot; 2012 Dec; 105(5):353-60. PubMed ID: 22886433
[TBL] [Abstract][Full Text] [Related]
19. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.
Viganò A; Mora S; Testolin C; Beccio S; Schneider L; Bricalli D; Vanzulli A; Manzoni P; Brambilla P
J Acquir Immune Defic Syndr; 2003 Apr; 32(5):482-9. PubMed ID: 12679698
[TBL] [Abstract][Full Text] [Related]
20. Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome.
Soares LR; da Silva DC; Gonsalez CR; Batista FG; Fonseca LA; Duarte AJ; Casseb J
Rev Inst Med Trop Sao Paulo; 2015; 57(2):105-10. PubMed ID: 25923888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
